Virtual Library
Start Your Search
A. Agbaria
Author of
-
+
P1.02 - Poster Session with Presenters Present (ID 454)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.02-032 - Diagnosis and Treatment of EGFR Mutated NSCLC among Arabic Patients (ID 5306)
14:30 - 14:30 | Author(s): A. Agbaria
- Abstract
Background:
About 15% of western patient population with advanced NSCLC harbor the epidermal growth factor receptor (EGFR) mutation compared to about 50% in the Asian population. These mutations are more frequently found in NSCLC with an adenocarcinoma histology, in women, East Asians and never smokers. EGFR tyrosine kinase inhibitors (TKIs) are the first-line treatment of choice for NSCLC patients harboring EGFR mutation. Nowadays there is only a scares information regarding EGFR epidemiology and response to EGFR TKI among other ethnicities, although there has been limited reports regarding increased rate of EGFR mutation among arabic patients.
Methods:
Single institution retrospective analysis of serial advanced NSCLC patients tested for EGFR mutation in 2011-2015. Information was obtained using the medical records.
Results:
Of 616 patients with advanced NSCLC tested for EGFR in our institutions in 2011-2015, there were a total of 134 Arabic patients, 38 of them harboring EGFR mutation (28%), as opposed to 64 (13%) among the non-arabic population. Twenty patients had exon 19 deletion, 9 patients had L858R and 1 patient had exon 21 mutation. The median age at diagnosis was 58 (39-80), 22 patients were males and 16 females, of them- 13 were never smokers, 5 are previous smokers, and 20 are active smokers. Thirty-six patients had adenocarcinoma histology while 2 patients had carcinosarcoma and squamous cell carcinoma. The median survival was longer than 9 months. Thirty patients were treated with EGFR TKI, 27 of them as 1[ST] line treatment, and 3 as 2[ND] line treatment. Of the 30 patients treated with EGFR TKI, 69% had partial response, 16% had stable disease.
Conclusion:
Among Arabic patients with NSCLC, the frequency of EGFR mutation is higher than in western population, and is more frequent among males and smokers. The response to EGFR TKI matches the reported literature.
